Biogen is after one key thing: the perfect dose.
Highly anticipated data due out next week on its experimental Alzheimer's medicine could show whether aducanumab will be among the first drugs to slow the cognitive declines associated with the disease.
If the medicine continues to perform the way the data have suggested so far, the impact would be enormous: Alzheimer's affects more than 5 million Americans now—a number expected to triple by 2050 without interventions. Analysts say the drug has a potential market opportunity of $20 billion a year.
On Wednesday, at the Alzheimer's Association International Conference in Washington, D.C., the company will present the results of what some hope may be the Goldilocks dose: highly effective, without too many side effects.